A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Safety and Efficacy of ANG-3070 in Patients With Primary Glomerular Disease and Persistent Proteinuria

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANG 3070 (Primary)
Indications Focal segmental glomerulosclerosis; IgA nephropathy; Kidney disorders; Proteinuria
Focus Pharmacokinetics
Acronyms JUNIPER
Sponsors Angion Biomedica

29 Jun 2022 According to an Angion Biomedica media release, the company has discontinued this study based on the evaluation that the occurrence of a potential safety signal of an unexpected and substantial decline in kidney function in a patient in the trial's drug treatment arm.
29 Jun 2022 Status changed from recruiting to discontinued, according to an Angion Biomedica media release.
12 Jan 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com